Researchers have made significant strides in treating Kawasaki disease, a rare condition primarily affecting young children. The European Commission has granted Orphan Drug Designation for infliximab, a medication previously approved for other conditions, to treat Kawasaki disease. This follows a similar designation from the U.S. Food and Drug Administration (FDA). The KIDCARE trial demonstrated that infliximab is more effective than the current standard treatment, intravenous immunoglobulin (IVIG), for children who do not respond to IVIG.

This development is crucial for parents concerned about their children’s heart health. Kawasaki disease can lead to serious complications, including coronary artery aneurysms, if not treated effectively. The KIDCARE trial, which involved 103 children with IVIG-resistant Kawasaki disease, showed that infliximab can reduce fever duration, the need for additional treatments, and hospitalization time. This means that children who struggle with this disease might soon have a more reliable treatment option that could improve their overall health outcomes.

The evidence supporting infliximab’s use comes from the KIDCARE trial, a robust study that provides strong data on its effectiveness and safety. While the trial’s results are promising, infliximab is still in the regulatory approval process for this specific use in Kawasaki disease. The Orphan Drug Designation helps facilitate the development of treatments for rare diseases, but it does not guarantee that the drug will be available immediately. Parents of children diagnosed with Kawasaki disease should stay informed about new treatment options as they become available.

Source: globenewswire.com